GlymaxX technology, developed by ProBioGen, prevents the addition of the sugar "fucose" to the N-linked antibody carbohydrate part by antibody producing cells
AstraZeneca has signed a multi-product commercial license agreement with AstraZeneca to use the GlymaxX technology. Following evaluation of the technology under a research license, AstraZeneca will now continue to use the platform, integrating it into drug discovery activity.
GlymaxX improves target cell killing orchestrated by natural killer cells, thereby enhances antibody-dependent cell-mediated cytotoxicity (ADCC), the company says. It allows modification of existing cell lines or creation of additional ones. Using the tech, the same modified cell line can produce antibodies with varying levels of fucosylation.
ProBioGen's Chief Business Officer, Dr Gabriele Schneider, said: "We are delighted that AstraZeneca decided to implement our technology, which has shown great potential in making molecules more potent and efficient."